We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TEM Q4 Earnings Miss, Revenues Beat, Stock Down in After-Market
Read MoreHide Full Article
Key Takeaways
TEM reported Q4 revenues of $367.2M, up 83% YoY, but earnings missed estimates.
Diagnostics revenues jumped 121.6%, driven by Oncology and Hereditary volume growth.
TEM guided 2026 revenues of $1.59B and adjusted EBITDA of $65M, targeting 25% growth.
Tempus AI, Inc. (TEM - Free Report) reported a fourth-quarter 2025 adjusted loss of 4 cents per share compared with the year-ago quarter’s loss of 16 cents. The metric was wider than the Zacks Consensus Estimate of loss by 66.7%.
GAAP loss per share was 30 cents compared with the year-ago quarter’s GAAP loss of 8 cents.
Full-year 2025 adjusted loss was 61 cents per share compared with the year-ago quarter’s loss of $1.54 per share.
TEM’s Revenues
Fourth-quarter revenues totaled $367.2 million, which beat the Zacks Consensus Estimate by 0.1%. The top line surged 83% on a year-over-year basis.
Full-year 2025 revenues totaled $1.27 billion, up 83.3% on a year-over-year basis.
Following the announcement, shares of Tempus AI declined 3.7% in after-market trading yesterday, reflecting investor reaction to the company’s reported quarterly operating loss.
Details of TEM’s Q4 Revenues
In the fourth quarter, Diagnostics generated revenues of $266.9 million, representing a 121.6% year-over-year increase.
Within this, Oncology volume grew 29% year over year and Hereditary volume rose 23%.
The Data and Applications segment reported sales of $100.4 million, up 25.1% year over year. This was driven by Insights (data licensing), which grew 69.5% year over year.
TEM’s Margin Performance
The gross profit in the fourth quarter was $237.7 million, up 94.7% from the year-ago quarter’s level. The adjusted gross margin expanded 391 bps to 64.7% despite a 64.7% rise in the cost of revenues.
Total adjusted operating expenses were $259 million, up 83.8% from the year-ago quarter’s level. The company incurred an operating loss of $21.3 million compared with the year-ago quarter’s loss of $18.8 million.
TEM’s Liquidity Position
At the end of the fourth quarter of 2025, the company had cash and cash equivalents of $604.8 million compared with $340.9 million at the end of the fourth quarter of 2024.
Cumulative net cash used in investing activities at the end of the reported quarter was $398.3 million compared with $130.4 million a year ago.
Tempus AI’s Full-Year 2026 Outlook
The company provided its guidance for 2026. Full-year revenues are expected to be $1.59 billion, indicating nearly 25% annual growth. The Zacks Consensus Estimate for revenues is pinned at $1.56 billion.
Adjusted EBITDA for the year is expected to be $65 million.
Our Take on TEM Stock
Tempus AI ended the fourth quarter of 2025 on a mixed note, wherein earnings missed estimates but revenues topped. The company witnessed a significant reacceleration of its clinical volumes. It achieved several milestones in the fourth quarter, including its selection by Northwestern Medicine to expand genomic testing access for oncology patients across the health system.
TEM also launched Paige Predict, an AI-powered digital pathology suite. It entered into a multi-year strategic collaboration with NYU Langone Health, centered on a prospective observational study.
The company’s quarterly operating loss looks discouraging.
TEM’s Zacks Rank and Key Picks
Tempus AI currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Cardinal Health (CAH - Free Report) and Align Technology (ALGN - Free Report) .
Intuitive Surgical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted EPS of $2.53, which surpassed the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 12.7% rise. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.24%.
Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter fiscal 2026 adjusted EPS of $2.63, which outpaced the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion topped the Zacks Consensus Estimate by 0.9%.
CAH has a long-term earnings growth rate of 15% compared with the industry’s 9.6% rise. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 9.3%.
Align Technology, carrying a Zacks Rank #2 at present, posted a fourth-quarter 2025 adjusted EPS of $3.29, which exceeded the Zacks Consensus Estimate by 10.1%. Revenues of $1.05 billion outperformed the Zacks Consensus Estimate by 5.3%.
ALGN has an estimated long-term earnings growth rate of 10.1% compared with the industry’s 9.5% rise. The company’s earnings outpaced estimates in three of the trailing four quarters and missed in one, the average surprise being 6.16%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
TEM Q4 Earnings Miss, Revenues Beat, Stock Down in After-Market
Key Takeaways
Tempus AI, Inc. (TEM - Free Report) reported a fourth-quarter 2025 adjusted loss of 4 cents per share compared with the year-ago quarter’s loss of 16 cents. The metric was wider than the Zacks Consensus Estimate of loss by 66.7%.
GAAP loss per share was 30 cents compared with the year-ago quarter’s GAAP loss of 8 cents.
Full-year 2025 adjusted loss was 61 cents per share compared with the year-ago quarter’s loss of $1.54 per share.
TEM’s Revenues
Fourth-quarter revenues totaled $367.2 million, which beat the Zacks Consensus Estimate by 0.1%. The top line surged 83% on a year-over-year basis.
Full-year 2025 revenues totaled $1.27 billion, up 83.3% on a year-over-year basis.
Following the announcement, shares of Tempus AI declined 3.7% in after-market trading yesterday, reflecting investor reaction to the company’s reported quarterly operating loss.
Details of TEM’s Q4 Revenues
In the fourth quarter, Diagnostics generated revenues of $266.9 million, representing a 121.6% year-over-year increase.
Within this, Oncology volume grew 29% year over year and Hereditary volume rose 23%.
The Data and Applications segment reported sales of $100.4 million, up 25.1% year over year. This was driven by Insights (data licensing), which grew 69.5% year over year.
TEM’s Margin Performance
The gross profit in the fourth quarter was $237.7 million, up 94.7% from the year-ago quarter’s level. The adjusted gross margin expanded 391 bps to 64.7% despite a 64.7% rise in the cost of revenues.
Total adjusted operating expenses were $259 million, up 83.8% from the year-ago quarter’s level. The company incurred an operating loss of $21.3 million compared with the year-ago quarter’s loss of $18.8 million.
TEM’s Liquidity Position
At the end of the fourth quarter of 2025, the company had cash and cash equivalents of $604.8 million compared with $340.9 million at the end of the fourth quarter of 2024.
Cumulative net cash used in investing activities at the end of the reported quarter was $398.3 million compared with $130.4 million a year ago.
Tempus AI’s Full-Year 2026 Outlook
The company provided its guidance for 2026. Full-year revenues are expected to be $1.59 billion, indicating nearly 25% annual growth. The Zacks Consensus Estimate for revenues is pinned at $1.56 billion.
Tempus AI, Inc. Price, Consensus and EPS Surprise
Tempus AI, Inc. price-consensus-eps-surprise-chart | Tempus AI, Inc. Quote
Adjusted EBITDA for the year is expected to be $65 million.
Our Take on TEM Stock
Tempus AI ended the fourth quarter of 2025 on a mixed note, wherein earnings missed estimates but revenues topped. The company witnessed a significant reacceleration of its clinical volumes. It achieved several milestones in the fourth quarter, including its selection by Northwestern Medicine to expand genomic testing access for oncology patients across the health system.
TEM also launched Paige Predict, an AI-powered digital pathology suite. It entered into a multi-year strategic collaboration with NYU Langone Health, centered on a prospective observational study.
The company’s quarterly operating loss looks discouraging.
TEM’s Zacks Rank and Key Picks
Tempus AI currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Cardinal Health (CAH - Free Report) and Align Technology (ALGN - Free Report) .
Intuitive Surgical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted EPS of $2.53, which surpassed the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 12.7% rise. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.24%.
Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter fiscal 2026 adjusted EPS of $2.63, which outpaced the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion topped the Zacks Consensus Estimate by 0.9%.
CAH has a long-term earnings growth rate of 15% compared with the industry’s 9.6% rise. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 9.3%.
Align Technology, carrying a Zacks Rank #2 at present, posted a fourth-quarter 2025 adjusted EPS of $3.29, which exceeded the Zacks Consensus Estimate by 10.1%. Revenues of $1.05 billion outperformed the Zacks Consensus Estimate by 5.3%.
ALGN has an estimated long-term earnings growth rate of 10.1% compared with the industry’s 9.5% rise. The company’s earnings outpaced estimates in three of the trailing four quarters and missed in one, the average surprise being 6.16%.